{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:37:38Z","timestamp":1760146658959,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objective: To investigate the effect of mycophenolate mofetil (MMF) and rituximab (RTX) on pulmonary function test (PFT) results in a mixed cohort of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), longitudinally followed up for 1 year in a single academic center. Methods: Patients with CTD-ILD were identified in electronic medical records from 1 January 2009 to 30 April 2019. Prescribed MMF and RTX doses, dosage changes, and therapy plans were analyzed individually with improvement in PFT outcomes determined using multivariable linear regression models during 12-month follow-up. Results: Forty-seven patients with CTD-ILD, treated with MMF, RTX, or both, were included. Patients on combined MMF and RTX had worse PFT outcomes at baseline compared with patients on monotherapy. Substantial improvement was observed among all PFT outcomes from baseline to 12 months, regardless of medication dosage or therapy plans. The diffusing capacity of the lungs for carbon monoxide (DLCO) worsened by an average of 7.21 mL\/(min*mmHg) (95% CI, 4.08\u201310.33; p &lt; 0.001) among patients on RTX compared to combined therapy. Patients on higher doses of MMF at baseline experienced an average increase of 0.93 (95% CI, 0.04\u20131.82) units in DLCO from baseline to 6 months (p = 0.04) and a 2.79% (95% CI, 0.61\u20134.97%) increase in DLCO from 6 to 12 months (p = 0.02) within patients on concurrent RTX at 6-month follow-up. Conclusions: The treatment of CTD-ILD with MMF and\/or RTX was associated with overall improvement in PFT outcomes. Combined therapy resulted in significant improvements in DLCO compared with monotherapy. Higher doses of MMF also provided greater improvements in DLCO.<\/jats:p>","DOI":"10.3390\/diagnostics14232702","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:00:10Z","timestamp":1733130010000},"page":"2702","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal Study of Patients with Connective Tissue Disease\u2013Interstitial Lung Disease and Response to Mycophenolate Mofetil and Rituximab"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-2962","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-1633","authenticated-orcid":false,"given":"Sehreen","family":"Mumtaz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-3981","authenticated-orcid":false,"given":"Hassan Z.","family":"Baig","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"},{"name":"Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Mira-Avendano","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Rojas","sequence":"additional","affiliation":[{"name":"Division of Thoracic, Cardiac Radiology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-7394","authenticated-orcid":false,"given":"Justin T.","family":"Stowell","sequence":"additional","affiliation":[{"name":"Division of Thoracic, Cardiac Radiology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Lesser","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalmali R.","family":"Borkar","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3627-4399","authenticated-orcid":false,"given":"Vikas","family":"Majithia","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Abril","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.autrev.2013.05.001","article-title":"Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis","volume":"12","author":"Marigliano","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s10067-016-3357-z","article-title":"Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Krause","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.mayocp.2018.09.002","article-title":"Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases","volume":"94","author":"Abril","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fernandes, L., Nasser, M., Ahmad, K., and Cottin, V. (2019). Interstitial Pneumonia With Autoimmune Features (IPAF). Front. Med., 6.","DOI":"10.3389\/fmed.2019.00209"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Parambil","year":"2013","journal-title":"Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cassone, G., Sebastiani, M., Vacchi, C., Erre, G.L., Salvarani, C., and Manfredi, A. (2021). Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: A narrative review. Drugs Context, 10.","DOI":"10.7573\/dic.2020-8-8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Atienza-Mateo, B., Remuzgo-Mart\u00ednez, S., Prieto-Pe\u00f1a, D., Cuesta, V.M.M., Iturbe-Fern\u00e1ndez, D., Llorca, J., S\u00e1nchez-Bilbao, L., Corrales, A., Rodr\u00edguez, G.B., and G\u00f3mez-Rom\u00e1n, J.J. (2020). Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103070"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.semarthrit.2020.08.004","article-title":"Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression","volume":"50","author":"Lluch","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review","volume":"45","author":"Doyle","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e000384","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"EVER-ILD investigators and the OrphaLung network. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): A double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.rmr.2014.07.013","article-title":"Pulmonary manifestations of antisynthetase syndrome","volume":"32","author":"Jouneau","year":"2015","journal-title":"Rev. Mal. Respir."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101503","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2174\/0929867322666150514094935","article-title":"Antisynthetase syndrome: A review of etiopathogenesis, diagnosis and management","volume":"22","author":"Mirrakhimov","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"Gerbino","year":"2008","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-010-1498-z","article-title":"Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease","volume":"29","author":"Koutroumpas","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","article-title":"Effect of mycophenolate sodium in scleroderma-related interstitial lung disease","volume":"30","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","article-title":"Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease","volume":"102","author":"Zamora","year":"2008","journal-title":"Respir. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-Term Treatment with Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: A retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur. J. Radiol."},{"key":"ref_31","first-page":"884","article-title":"Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): Clinical, serological and radiological heterogeneity","volume":"50","author":"Rathnapala","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/23\/2702\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:43:15Z","timestamp":1760114595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/23\/2702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":32,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["diagnostics14232702"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14232702","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2024,11,30]]}}}